DNA markers in molecular diagnostics for hepatocellular carcinoma

References

• Ferlay J, Soerjomataram I, Ervik M DR, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancerbase No. 11. Internet International Agency for Research on Cancer: Lyon, France; 2013. Available from: http://globocan.iarc.fr [Last accessed on 23 April 2014]
   Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2
   PubMed Web of Science ®Google Scholar
• Cancer facts and figures. American Cancer Society 2012
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2010. National Cancer Institute. Bethesda MD. 2013. Available from: http://seer.cancer.gov/csr/1975_2010/ based on November 2012 SEER data submission, posted to the SEER web site
   Google Scholar
• European Association for the Study of the Liver, European Organization for Research, Treatment of Cancer. EASL–EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-43
   PubMedGoogle Scholar
• Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008;29(7):1299-305
   PubMedGoogle Scholar
• Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34(4):570-5
   PubMed Web of Science ®Google Scholar
• Moriya S, Morimoto M, Numata K, et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma. Anticancer Res 2013;33(3):997-1001
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789-99
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28
   PubMed Web of Science ®Google Scholar
• Ozen C, Yildiz G, Dagcan AT, et al. Genetics and epigenetics of liver cancer. New Biotechnol 2013;30(4):381-4
   PubMed Web of Science ®Google Scholar
• Nault JC, Zucman-Rossi J. Genetics of hepatocellular carcinoma: the next generation. J Hepatol 2014;60(1):224-6
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 2013;340(2):234-40
   PubMedGoogle Scholar
• Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013;23(9):1422-33
   PubMed Web of Science ®Google Scholar
• Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 2013;58(5):1693-702
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44(7):765-9
   PubMed Web of Science ®Google Scholar
• Shen J, Wang S, Zhang YJ, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012;55(6):1799-808
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44(6):694-8
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44(7):760-4
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245-55
   PubMed Web of Science ®Google Scholar
• Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003;39(6):1076-84
   PubMed Web of Science ®Google Scholar
• Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42(1):27-34
   PubMed Web of Science ®Google Scholar
• Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001;20(2):99-104
   PubMedGoogle Scholar
• Sterling RK, Jeffers L, Gordon F, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007;102(10):2196-205
   PubMed Web of Science ®Google Scholar
• Koike Y, Shiratori Y, Sato S, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001;91(3):561-9
   PubMedGoogle Scholar
• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-37
   PubMed Web of Science ®Google Scholar
• Nomoto S, Kinoshita T, Kato K. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 2007;97(9):1260-5
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29(36):4989-5005
   PubMed Web of Science ®Google Scholar
• Marquardt JU, Thorgeirsson SS. SnapShot: hepatocellular carcinoma. Cancer Cell 2014;25(4):550-0. e551
   PubMed Web of Science ®Google Scholar
• Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn 2011;11(3):333-43
   PubMed Web of Science ®Google Scholar
• Klee EW, Hoppman-Chaney NL, Ferber MJ. Expanding DNA diagnostic panel testing: is more better? Expert Rev Mol Diagn 2011;11(7):703-9
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4
   PubMedGoogle Scholar
• Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010;5(3):e9749
   PubMed Web of Science ®Google Scholar
• Ammerpohl O, Pratschke J, Schafmayer C, et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 2011;130(6):1319-28
   PubMedGoogle Scholar
• Revill K, Wang T, Lachenmayer A, et al. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 2013;145(6):1424-1435.e1425
   PubMed Web of Science ®Google Scholar
• Shitani M, Sasaki S, Akutsu N, et al. Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumor Biol 2012;33(5):1307-17
   PubMedGoogle Scholar
• Chang H, Yi B, Li L, et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 2008;85(2):96-100
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Rossner P Jr, Chen Y, et al. Aflatoxin B 1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 2006;119(5):985-91
   PubMedGoogle Scholar
• Mora J, Urgell E, Farre A, et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem 2006;52(7):1448-9
   PubMedGoogle Scholar
• Su YH, Wang M, Block TM, et al. Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci 2004;1022(1):81-9
   PubMedGoogle Scholar
• Lin SY, Dhillon V, Jain S, et al. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn 2011;13(5):474-84
   PubMed Web of Science ®Google Scholar
• Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338(21):1481-7
   PubMed Web of Science ®Google Scholar
• Chan AKC, Chiu RWK, Lo YMD. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem 2003;40:122-30
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17:89-97
   PubMed Web of Science ®Google Scholar
• Lui YYN, Woo KS, Wang AYM, et al. Origin of plasma cell-free DNA after solid organ transplantation. Clin Chem 2003;49(3):495
   PubMed Web of Science ®Google Scholar
• Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004;62A(1):46-53
   Google Scholar
• Chan KCA, Leung SF, Yeung SW, et al. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res 2008;14(15):4809-13
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Schmidt B. Cell-free DNA resuscitated for tumor testing. Nat Med 2008;14(9):914-15
   PubMed Web of Science ®Google Scholar
• Narayan A, Carriero NJ, Gettinger SN, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012;72(14):3492-8
   PubMed Web of Science ®Google Scholar
• Papadopoulou E, Davilas E, Sotiriou V, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncol Res 2004;14:439-45
   PubMedGoogle Scholar
• Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006;52(10):1833-42
   PubMed Web of Science ®Google Scholar
• Iacopetta B. TP53 mutations in colorectal cancer. Hum Mutat 2003;21:271-6
   PubMed Web of Science ®Google Scholar
• Su P, Zhang L, Wan W, et al. Detection of p53 gene mutation in the plasma of gastric cancer patients. Beijing Da Xue Xue Bao 2005;37(5):523-6
   PubMedGoogle Scholar
• Cohen Y, Singer G, Lavie O, et al. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003;9(8):2981-4
   PubMedGoogle Scholar
• Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007;23(1):73-87
   PubMed Web of Science ®Google Scholar
• Yan PS, Shi H, Rahmatpanah F, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 2003;63(19):6178-86
   PubMedGoogle Scholar
• Brucher BLDM, Gedder H, Langner C, et al. Hypermethylation of hMLH1, HPP1, p14 ARF, p16 INK4A, and APC in primary adenocarcinomas of the small bowel. Int J Cancer 2008;1298-302
   Google Scholar
• Hsu IC, Metcaf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8
   PubMed Web of Science ®Google Scholar
• Kirk GD, Lesi OA, Mendy M, et al. 249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005;24(38):5858-67
   PubMedGoogle Scholar
• Kuang SY, Lekawanvijit S, Maneekarn N, et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005;14(2):380-4
   PubMedGoogle Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochem Biophys Acta 2002;1602(1):73-87
   PubMed Web of Science ®Google Scholar
• Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002;2(12):910-17
   PubMed Web of Science ®Google Scholar
• Sherr CJ. The pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60(14):3689-95
   PubMed Web of Science ®Google Scholar
• Ulivi P, Capelli L, Valgiusti M, et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med 2012;10(1):87
   PubMedGoogle Scholar
• Nishida N, Nishimura T, Nagasaka T, et al. Extensive methylation is associated with β-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res 2007;67(10):4586-94
   PubMedGoogle Scholar
• Edamoto Y, Hara A, Biernat W, et al. Alternations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003;106:334-41
   PubMedGoogle Scholar
• Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008;949-52
   PubMedGoogle Scholar
• Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107(3):526-31
   PubMed Web of Science ®Google Scholar
• Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics 2000;1:123-40
   PubMedGoogle Scholar
• Zain SM, Mohamed R, Cooper DN, et al. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. PLoS One 2014;9(4):e95604
   Google Scholar
• Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2012;35(1):32-41
   PubMed Web of Science ®Google Scholar
• Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7(3):e1001324
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40(12):1461-5
   PubMed Web of Science ®Google Scholar
• Jain S, Chang TT, Hamilton JP, et al. Methylation of the CpG Sites only on the sense strand of the APC gene is specific for hepatocellular Carcinoma. PLoS One 2011;6(11):e26799
   Web of Science ®Google Scholar
• Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163(3):1101-7
   PubMed Web of Science ®Google Scholar
• Csepregi A, Rocken C, Hoffmann J, et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134(5):579-89
   PubMed Web of Science ®Google Scholar
• Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163(4):1371-8
   PubMed Web of Science ®Google Scholar
• Nishida N, Arizumi T, Takita M, et al. Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. Oncology 2013;84:82-7
   PubMed Web of Science ®Google Scholar
• Huang ZH, Hu Y, Hua D, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011;91(3):702-7
   PubMedGoogle Scholar
• Liu JB, Zhang YX, Zhou SH, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol 2011;17(42):4718-24
   PubMed Web of Science ®Google Scholar
• Iyer P, Zekri AR, Hung CW, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2009;88(1):107-11
   PubMedGoogle Scholar
• Wu Y, Li J, Sun CY, et al. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells. Neoplasma 2012;59(3):326-32
   PubMedGoogle Scholar
• Huang J, Zhang YL, Teng XM, et al. Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 2007;7(1):126
   PubMedGoogle Scholar
• Shih YL, Shyu RY, Hsieh CB, et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006;107(3):579-90
   PubMedGoogle Scholar
• Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 2008;43(5):378-89
   PubMed Web of Science ®Google Scholar
• Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-5
   PubMed Web of Science ®Google Scholar
• Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49(3):821-31
   PubMed Web of Science ®Google Scholar
• de La Coste A, Romagnolo B, Billuart P. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95(15):8847-51
   PubMed Web of Science ®Google Scholar
• Huang H, Fujii H, Sankila A. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155(6):1795-801
   PubMed Web of Science ®Google Scholar
• Legoix P, Bluteau O, Bayer J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18(27):4044-6
   PubMedGoogle Scholar
• Miyoshi Y, Iwao K, Nagasawa Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58(12):2524-7
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Roberts LR, Aderca IN. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21(31):4863-71
   PubMed Web of Science ®Google Scholar
• Terris B, Pineau P, Bregeaud L. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18(47):6583-8
   PubMedGoogle Scholar
• Gordon M, Baksh S. RASSF1A: not a prototypical Ras effector. Small GTPases 2011;2(3):148-57
   PubMedGoogle Scholar
• Song MS, Song SJ, Ayad NG, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6(2):129-37
   PubMedGoogle Scholar
• Vos MD, Martinez A, Elam C, et al. A Role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004;64(12):4244-50
   PubMedGoogle Scholar
• Liu L, Tommasi S, Lee DH, et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003;22(50):8125-36
   PubMedGoogle Scholar
• Shivakumar L, Minna J, Sakamaki T, et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. MolCell Biol 2002;22(12):4309-18
   PubMed Web of Science ®Google Scholar
• Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120(18):3163-72
   PubMedGoogle Scholar
• Matsuda Y, Ichida T, Matsusawa J, et al. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999;116:394-400
   PubMedGoogle Scholar
• Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001;48:372-7
   PubMed Web of Science ®Google Scholar
• Jackson PE. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001;61:33-5
   PubMed Web of Science ®Google Scholar
• Stern MC, Umbach DM, Yu MC, et al. Hepatitis B, aflatoxin B1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People’s Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001;10(6):617-25
   PubMed Web of Science ®Google Scholar
• Yeo W, Wong N, Wong WL, et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005;25(2):266-72
   PubMed Web of Science ®Google Scholar
• Hosny G, Farahat N, Tayel H, Hainaut P. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett 2008;264(2):201-8
   PubMed Web of Science ®Google Scholar
• Igetei R, Otegbayo J, Ndububa D, et al. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol 2008;7(4):339-44
   PubMed Web of Science ®Google Scholar
• Toh ST, Jin Y, Liu L, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis 2013;34(4):787-98
   PubMedGoogle Scholar
• Li W, Zeng X, Lee NP, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics 2013;102(4):338-44
   PubMedGoogle Scholar
• Ding D, Lou X, Hua D, et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing–based approach. PLoS Genet 2012;8(12):e1003065
   Google Scholar
• Chen YL, Jeng YM, Chang CN, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg 2014;12(7):659-65
   PubMed Web of Science ®Google Scholar
• Pinyol R, Tovar V, Llovet JM. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. J Hepatol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011;43(9):828-9
   PubMed Web of Science ®Google Scholar
• Endo M, Yasui K, Zen Y, et al. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int 2013;33(1):105-17
   PubMed Web of Science ®Google Scholar
• Grabinski N, Ewald F, Hofmann B, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012;11(1):85
   PubMedGoogle Scholar
• Villanueva A, Chiang DY, Newell P, et al. Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology 2008;135(6):1972-83. e1911
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WL, Zhang Y, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007;37(5):389-96
   PubMedGoogle Scholar
• Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002;2(1):29
   PubMedGoogle Scholar
• Hua D, Hu Y, Wu YY, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol 2011;91(1):455-60
   PubMedGoogle Scholar
• Nishida N, Nagasaka T, Nishimura T, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008;47(3):908-18
   PubMed Web of Science ®Google Scholar
• Jain S, Chen S, Chang KC, et al. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One 2012;7(4):e35789
   Google Scholar
• Harder J, Opitz OG, Brabender J, et al. Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int J Cancer 2008;122(12):2800-4
   PubMedGoogle Scholar
• Wong CM, Ng IOL. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2007;28(2):160-74
   PubMedGoogle Scholar
• Wong CM, Ng YL, Lee JM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007;45:1129-38
   PubMed Web of Science ®Google Scholar
• Sun FK, Fan YC, Zhao J, et al. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig Dis Sci 2013;58(4):1010-15
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-36
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365(12):1118-27
   PubMed Web of Science ®Google Scholar
• Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008;48(5):848-57
   PubMedGoogle Scholar
• Jain S, Wojdacz TK, Su YH. Challenges for the application of DNA methylation biomarkers in molecular diagnostic testing for cancer. Expert Rev Mol Diagn 2013;13(3):283-94
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJH, Niessen HEC, Derks S, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin Cancer Res 2011;17(13):4225-31
   PubMed Web of Science ®Google Scholar
• Jackson PE, Kuang SY, Wang JB, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 2003;24(10):1657-63
   PubMed Web of Science ®Google Scholar
• Kirk GD. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst 2000;92:148-53
   PubMedGoogle Scholar
• Lleonart ME, Kirk GD, Villar S, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 2005;14(12):2956-62
   PubMedGoogle Scholar
• Wong IHN, Dennis Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59(1):71-3
   PubMed Web of Science ®Google Scholar
• Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62(2):371-5
   PubMed Web of Science ®Google Scholar
• Wang J, Qin Y, Li B, et al. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 2006;39(4):344-8
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Sakaida I, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta 2011;412(1-2):152-8
   PubMed Web of Science ®Google Scholar
• Chan KCA, Jiang P, Chan CWM, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 2013;110(47):18761-8
   PubMed Web of Science ®Google Scholar
• Swanton C. Plasma-derived tumor DNA analysis at whole-genome resolution. Clin Chem 2013;59(1):6-8
   PubMedGoogle Scholar
• Chan KCA, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59(1):211-24
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4(136):136ra168
   Web of Science ®Google Scholar
• Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101(15):1066-82
   PubMedGoogle Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124(2):327-34
   PubMed Web of Science ®Google Scholar
• Guo X, Jin Y, Qian G, Tu H. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008;49(5):718-25
   PubMedGoogle Scholar
• Wang Z, Tanaka Y, Huang Y, et al. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol 2007;45(5):1491-6
   PubMed Web of Science ®Google Scholar
• Zhu R, Zhang HP, Yu H, et al. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients. Pathol Res Pract 2008;204(10):731-42
   PubMedGoogle Scholar
• Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57(1):91-7
   PubMed Web of Science ®Google Scholar
• Tong MJ, Blatt LM, Kao J-H, et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006;2(41):6620
   Google Scholar
• Jang J, Lee Y, Kim M, et al. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat 2007;14(3):169-75
   PubMedGoogle Scholar
• Yuan JM, Ambinder A, Fan Y, et al. Prospective evaluation of hepatitis B 1762T/1764A mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2009;18(2):590-4
   PubMedGoogle Scholar
• Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100(16):1134-43
   PubMedGoogle Scholar
• Fang ZL, Sabin CA, Dong BQ, et al. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol 2008;103(9):2254-62
   PubMedGoogle Scholar
• Lin SY, Jain S, Song W, et al. Strategic assay developments for detection of HBV 1762T/1764A double mutation in urine of patients with HBV-associated hepatocellular carcinomas. In: Lau WY, editor. Hepatocellular carcinoma - clinical research. Intech; Croatia: 2012
   Google Scholar
• Yuan J, Zhou B, Tanaka Y, et al. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J Clin Virol 2007;39(2):87-93
   PubMedGoogle Scholar
• Lindh M, Hannoun C, Dhillon AP, et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179(4):775-82
   PubMedGoogle Scholar
• Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007;127(2):164-76
   PubMedGoogle Scholar
• Sugauchi F, Ohno T, Orito E, et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003;70(4):537-44
   PubMed Web of Science ®Google Scholar
• Fang ZL, Sabin CA, Dong BQ, et al. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case–control study. J Gen Virol 2008;89(11):2882-90
   PubMedGoogle Scholar
• Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007;133(5):1466-74
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Sa-nguanmoo P, Mahachai V, et al. A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int 2010;4(3):577-84
   PubMedGoogle Scholar
• Cho EY, Choi CS, Cho JH, Kim HC. Association between hepatitis B virus X gene mutations and clinical status in patients with chronic hepatitis B infection. Gut Liver 2011;5(1):70-6
   PubMedGoogle Scholar
• Jang JW, Chun JY, Park YM, et al. Mutational complex genotype of the hepatitis B virus X/precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci 2012;103(2):296-304
   PubMedGoogle Scholar
• Park Y, Jang J, Yoo S, et al. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat 2014;21(3):171-7
   PubMedGoogle Scholar
• Khan A, Al Balwi MA, Tanaka Y, et al. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. Int J Cancer 2013;133(12):2864-71
   PubMedGoogle Scholar
• Ouneissa R, Bahri O, Alaya-Bouafif NB, et al. Frequency and clinical significance of core promoter and precore region mutations in Tunisian patients infected chronically with hepatitis B. J Med Virol 2012;84(11):1719-26
   PubMedGoogle Scholar
• Zhang Y, Li C, Zhang Y, et al. Comparative analysis of CpG Islands among HBV genotypes. PLoS One 2013;8(2):e56711
   PubMed Web of Science ®Google Scholar
• Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009;19(3):438-51
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepatitis 2008;15(2):103-7
   PubMed Web of Science ®Google Scholar
• Pepe MS, Etzioni R, Feng Z, et al. Phases of Biomarker Development for Early Detection of Cancer. JNCI Cancer Spectrum 2001;93(14):1054-61
   PubMed Web of Science ®Google Scholar
• Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100(20):1432-8
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Developing molecular biomarkers for cancer. Science 2003;299(5613):1679-80
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102(19):1462-7
   PubMedGoogle Scholar
• Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012;72(23):6097-101
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Moeini A, Alsinet C, et al. Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 2012;39(4):473-85
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368(13):1199-209
   PubMed Web of Science ®Google Scholar
• Um TH, Kim H, Oh BK, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011;54(5):939-47
   PubMed Web of Science ®Google Scholar
• Wong CM, Fan ST, Ng IO. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001;92(1):136-45
   PubMed Web of Science ®Google Scholar
• Xu B, Di J, Wang Z, et al. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. Biochem Biophys Res Commun 2013;438(2):324-8
   PubMedGoogle Scholar
• Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010;4(1):423-32
   PubMed Web of Science ®Google Scholar
• Di Gioia S, Bianchi P, Destro A, et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006;6(1):89
   PubMedGoogle Scholar
• Nishida N, Nagasaka T, Nishimura T, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008;47:908-18
   PubMed Web of Science ®Google Scholar
• Honda K, Sbisà E, Tullo A. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998;77(5):776-82
   PubMed Web of Science ®Google Scholar
• Hayashi H, Sugio K, Matsumata T, et al. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 1995;22(6):1702-7
   PubMedGoogle Scholar
• Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007;26(15):2166-76
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73
   PubMed Web of Science ®Google Scholar
• Xie HJ, Bae HJ, Noh JH, et al. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 2009;56(2):136-42
   PubMed Web of Science ®Google Scholar
• Kuang SY, Jackson PE, Wang JB, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA 2004;101(10):3575-80
   PubMedGoogle Scholar
• Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One 2012;7(6):e37707
   Google Scholar
• Huang XH, Sun LH, Lu DD, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol 2003;9(4):692-5
   PubMed Web of Science ®Google Scholar
• Igetei R, Otegbayo JA, Lesi OA, et al. P53 codon 249 mutation and other risk factors among Nigerians with hepatocellular carcinoma. J Afr Cancer 2010;2(3):133-9
   Google Scholar
• Gouas DA, Villar S, Ortiz-Cuaran S, et al. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis 2012;33(6):1-6
   Google Scholar
• Ortiz-Cuaran S, Villar S, Gouas D, et al. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Lett 2013;331(1):46-51
   PubMedGoogle Scholar
• Carvalho F, Almeida Pereira T, Gonçalves P, et al. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep 2013;40(8):4883-7
   PubMedGoogle Scholar
• Özdemir F, Tiftikci A, Sancak S, et al. The prevalence of the mutation in codon 249 of the P53 gene in patients with hepatocellular carcinoma (HCC) in Turkey. J Gastrointest Canc 2010;41(3):185-9
   PubMedGoogle Scholar
• Kimbi GC, Kew MC, Yu MC, et al. 249serp53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20(8):1185-90
   PubMed Web of Science ®Google Scholar
• Mah YH, Hsu CS, Liu CH, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int 2011;5(3):814-21
   PubMedGoogle Scholar
• Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007;13(8):2378-84
   PubMed Web of Science ®Google Scholar
• Ahmed R, Salama H, Fouad A, et al. Detection of aberrant p16INK4A methylation in sera of patients with HCV-related liver diseases: an Egyptian study. Med Sci Monit 2010;19(9):CR410-15
   Google Scholar
• Huang G, Krocker JD, Kirk JL, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014;1-11
   PubMedGoogle Scholar
• Mohamed NA, Swify EM, Amin NF, et al. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 2012;13(3):111-15
   PubMedGoogle Scholar